The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Medtronic's revenues will contract -1.0% and EPS will expand 7.6%.
The average estimate for revenue is $4.01 billion. On the bottom line, the average EPS estimate is $0.85.
Last quarter, Medtronic reported revenue of $4.30 billion. GAAP reported sales were 3.1% higher than the prior-year quarter's $4.17 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.99. GAAP EPS of $0.95 for Q4 were 34% higher than the prior-year quarter's $0.71 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.6%, 50 basis points worse than the prior-year quarter. Operating margin was 29.5%, 40 basis points worse than the prior-year quarter. Net margin was 23.1%, 450 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $16.46 billion. The average EPS estimate is $3.66.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,733 members out of 1,825 rating the stock outperform, and 92 members rating it underperform. Among 495 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 478 give Medtronic a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Medtronic is outperform, with an average price target of $42.90.
Can your retirement portfolio provide you with enough income to last? You'll need more than Medtronic. Learn about crafting a smarter retirement plan in "The Shocking Can't-Miss Truth About Your Retirement." Click here for instant access to this free report.
- Add Medtronic to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Mazor Robotics Fell 10.8% in December
Shares fall by double-digits during a quiet month for the robotic surgery upstart. Is there something to worry about, or is the pullback just market noise?
How Safe Is Medtronic's Dividend?
The medical device manufacturer has a long history of rising dividends, but can its growth continue?
5 Dividend Aristocrats With the Fastest-Growing Dividends
The best kind of dividend stocks: long track records of dividend hikes -- and huge dividend increases.